Cali Biosciences leads breakthrough in post-operative pain management

Cali Biosciences Co., Ltd., a biotechnology company specializing in innovative drug development, recently conducted a study on CPL-01, a long-acting ropivacaine, for open inguinal hernia repair. The study, published in the scientific journal Hernia, revealed that CPL-01 offers superior pain relief compared to a placebo and the standard Naropin®. Patients experienced significantly reduced pain levels over 72 hours while requiring fewer opioids.

Dr. Tommy Xu, the study's lead author, emphasized the significance of these findings, highlighting CPL-01's exceptional performance. Dr. Erol Onel, Chief Medical Officer of Cali Biosciences US, LLC, pointed out that CPL-01, derived from ropivacaine, presents a safer option among long-acting local anesthetics.

Dr. Todd Bertoch, the study's principal investigator, reiterated CPL-01's safety profile, noting the absence of serious adverse events in the Phase 3 trial. PJ Chen, CEO of Cali Biosciences, expressed optimism about CPL-01's promising results and its potential to revolutionize post-operative pain management.

CPL-01, a sustained-release injectable form of ropivacaine, extends the duration of pain relief at the surgical site after a single administration. Cali Biosciences leveraged the PG-Depot drug delivery platform to achieve this extended analgesic effect.

Founded in 2021 in the Cayman Islands, Cali Biosciences is committed to developing cutting-edge pain management solutions through innovative drug delivery technologies. Focusing on non-opioid options for post-operative pain control, the company aims to meet the needs of healthcare professionals and patients globally with effective treatment choices.

The study conducted by Cali Biosciences demonstrates the potential of CPL-01 in enhancing post-operative pain management. With its superior pain relief and safety profile, CPL-01 offers a promising alternative for patients undergoing inguinal hernia repair and other surgical procedures. Cali Biosciences' dedication to advancing non-opioid solutions underscores its commitment to improving healthcare outcomes worldwide.